Abstract
BackgroundAnti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy showed remarkable efficacy in patients with relapsed or refractory multiple myeloma (RRMM). This phase 1 dose-escalation and expansion study...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have